Mutation of C/EBPalpha predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen

Blood
Marie Sigurd HasemannBo Torben Porse

Abstract

The CCAAT enhancer binding protein alpha (C/EBPalpha) is an important myeloid tumor suppressor that is frequently mutated in human acute myeloid leukemia (AML). We have previously shown that mice homozygous for the E2F repression-deficient Cebpa(BRM2) allele develop nonfatal AML with long latency and incomplete penetrance, suggesting that accumulation of secondary mutations is necessary for disease progression. Here, we use SRS19-6-driven retroviral insertional mutagenesis to compare the phenotypes of leukemias arising in Cebpa(+/+), Cebpa(+/BRM2), and Cebpa(BRM2/BRM2) mice, with respect to disease type, latency of tumor development, and identity of the retroviral insertion sites (RISs). Both Cebpa(+/BRM2) and Cebpa(BRM2/BRM2) mice preferentially develop myeloid leukemias, but with differing latencies, thereby demonstrating the importance of gene dosage. Determination of RISs led to the identification of several novel candidate oncogenes, some of which may collaborate specifically with the E2F repression-deficient allele of Cebpa. Finally, we used an in silico pathway analysis approach to extract additional information from single RISs, leading to the identification of signaling pathways which were preferentially deregulated in...Continue Reading

References

May 11, 1995·Nucleic Acids Research·R S DevonA J Brookes
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·D E ZhangD G Tenen
Dec 26, 2001·Nature Genetics·Danilo PerrottiBruno Calabretta
May 15, 2002·The Biochemical Journal·Dipak P Ramji, Pelagia Foka
Aug 20, 2002·Nature Genetics·Anders H LundMaarten van Lohuizen
Dec 11, 2002·British Journal of Haematology·C S ChimY L Kwong
Mar 28, 2003·Genes, Chromosomes & Cancer·Jennifer SnaddonJude Fitzgibbon
Apr 15, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Sahar Barjesteh van Waalwijk van Doorn-KhosrovaniRuud Delwel
Jul 4, 2003·The EMBO Journal·María J CalocaXosé R Bustelo
Dec 19, 2003·Nucleic Acids Research·Keiko AkagiNeal G Copeland
Jan 9, 2004·Current Biology : CB·Jeffrey L Salisbury
Jan 30, 2004·Journal of Virology·Stefan J ErkelandIvo P Touw
May 4, 2004·Nature Reviews. Cancer·Claus Nerlov
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Daniel HelblingThomas Pabst
Dec 3, 2004·The New England Journal of Medicine·Matthew L SmithJude Fitzgibbon
Jan 15, 2005·Current Biology : CB·Dan BairdRichard A Cerione
Jan 28, 2005·Leukemia·H LeroyC Preudhomme
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marianne BienzThomas Pabst
Mar 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lee-Yung ShihTzung-Chih Tang
Nov 1, 2005·Trends in Genetics : TIG·Peter D Aplan
Nov 22, 2005·Oncogene·A G UrenM van Lohuizen
Dec 2, 2005·Current Opinion in Hematology·Beatrice U Mueller, Thomas Pabst
Dec 20, 2005·Nucleic Acids Research·Paul van den IjsselBauke Ylstra
Feb 1, 2006·The Journal of Experimental Medicine·Hanna S RadomskaDaniel G Tenen
Mar 16, 2006·Journal of the National Cancer Institute·Yasuhiro TadaChristoph Plass
Apr 18, 2006·Biochimica Et Biophysica Acta·Mikkel Bruhn Schuster, Bo Torben Porse
Oct 4, 2006·The Journal of Clinical Investigation·Michelle B BowieConnie J Eaves

❮ Previous
Next ❯

Citations

Jan 24, 2013·Leukemia·G VolpeS Dumon
May 23, 2009·Nature Reviews. Cancer·Jaap Kool, Anton Berns
Aug 30, 2008·British Journal of Haematology·Tobias BenthausAnnika Dufour
May 9, 2019·Physiological Reviews·Julhash U Kazi, Lars Rönnstrand

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.